<SEC-DOCUMENT>0001213900-21-014720.txt : 20210311
<SEC-HEADER>0001213900-21-014720.hdr.sgml : 20210311
<ACCEPTANCE-DATETIME>20210311082825
ACCESSION NUMBER:		0001213900-21-014720
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20210311
DATE AS OF CHANGE:		20210311

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Inmune Bio, Inc.
		CENTRAL INDEX KEY:			0001711754
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				475205835
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-237368
		FILM NUMBER:		21731922

	BUSINESS ADDRESS:	
		STREET 1:		1200 PROSPECT STREET
		STREET 2:		SUITE 525
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		8589643720

	MAIL ADDRESS:	
		STREET 1:		1200 PROSPECT STREET
		STREET 2:		SUITE 525
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>ea137354-424b5_inmunebio.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Filed Pursuant to Rule 424(b)(5)<BR>
Registration No. 333-237368</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>PROSPECTUS SUPPLEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>(To the Prospectus Dated April 2, 2020) </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="image_001.jpg" ALT="" STYLE="height: 175px; width: 262px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$45,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INMUNE BIO, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">This prospectus
supplement and the accompanying base prospectus, which together we sometimes refer to as the prospectus, relate to the offer and
sale, from time to time, of <FONT STYLE="background-color: white">shares of our common stock having an aggregate gross sales price
of up to $</FONT>45,000,000<FONT STYLE="background-color: white">, through BTIG, LLC, or BTIG, acting as our sales agent</FONT>,
in accordance with the terms of a <FONT STYLE="background-color: white">sales agreement we have entered into with BTIG.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Sales of our common
stock, if any, under this prospectus supplement will be made by any method that is deemed to be an &ldquo;at the market offering&rdquo;
as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, or the Securities Act. BTIG <FONT STYLE="background-color: white">is
not required to sell any specific amount of securities, but will act as our sales agent using commercially reasonable efforts consistent
with its normal trading and sales practices, on mutually agreed terms between BTIG and us. There is no arrangement for funds to
be received in any escrow, trust or similar arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">BTIG will be entitled
to compensation at a fixed commission rate of 3.0% of the gross proceeds from the sale of our common stock on our behalf pursuant
to the sales agreement. In connection with the sale of the common stock on our behalf, BTIG will be deemed to be an &ldquo;underwriter&rdquo;
within the meaning of the Securities Act, and the compensation of BTIG will be deemed to be underwriting commissions or discounts.
We have agreed to provide indemnification and contribution to BTIG against certain civil liabilities, including liabilities under
the Securities Act or the Securities Exchange Act of 1934, as amended, or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">Our common stock is currently traded on
the Nasdaq Capital Market, or Nasdaq, under the symbol &ldquo;INMB.&rdquo; On March 5, 2021, the last reported sales price for
our common stock was $14.31 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">We are an &ldquo;emerging growth company&rdquo;
as that term is used in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, and, as such, have elected to comply
with certain reduced public company reporting requirements for this prospectus supplement, the accompanying prospectus and our
filings with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 24.5pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B>Investing in our common stock involves
a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page&nbsp;S-6 of this prospectus supplement and page&nbsp;5
of the accompanying prospectus. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white"><B>Neither the Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
supplement is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 85px; width: 330px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus supplement
is March 10, 2021. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 91%">&nbsp;</TD>
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS SUPPLEMENT</B></FONT></TD></TR>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-1</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-2</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-6</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-6</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-7</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DILUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-7</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-8</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">LEGAL MATTERS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-10</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-10</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_010"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-10</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#a_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INFORMATION INCORPORATED BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">S-10</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD COLSPAN="2" STYLE="padding-left: 12pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROSPECTUS</B></FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT INMUNE BIO</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; padding-left: 12pt; text-indent: -12pt"><A HREF="#b_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement and the accompanying
prospectus relate to the offering of our common stock. Before buying any of the common stock that we are offering, we urge you
to carefully read this prospectus supplement and the accompanying prospectus, together with the information incorporated by reference
as described under the headings &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Information
by Reference&rdquo; in this prospectus supplement. These documents contain important information that you should consider when
making your investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This document is in two parts. The first
part is this prospectus supplement, which describes the specific terms of this offering and also adds to and updates information
contained in the accompanying prospectus and the documents incorporated by reference herein or therein. The second part, the accompanying
prospectus, provides more general information. Generally, when we refer to this prospectus, we are referring to both parts of this
document combined. To the extent there is a conflict between the information contained in this prospectus supplement, on the one
hand, and the information contained in any document incorporated by reference into this prospectus supplement that was filed with
the Securities and Exchange Commission (the &ldquo;SEC&rdquo;), before the date of this prospectus supplement, on the other hand,
you should rely on the information in this prospectus supplement. If any statement in one of these documents is inconsistent with
a statement in another document having a later date&mdash;for example, a document incorporated by reference into this prospectus
supplement&mdash;the statement in the document having the later date modifies or supersedes the earlier statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We further note that the representations,
warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference
herein or in the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some
cases, for the purpose of allocating risk among the parties to such agreement, and should not be deemed to be a representation,
warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made.
Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state
of our affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should rely only on the information
contained or incorporated by reference in this prospectus supplement and the accompanying prospectus and any free writing prospectuses
we may provide to you in connection with this offering. We have not, and BTIG has not, authorized any other person to provide you
with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are
not, and BTIG is not, making an offer to sell or seeking an offer to buy our common stock under this prospectus in any jurisdiction
where the offer or sale is not permitted. Persons outside the United States who come into possession of this prospectus must inform
themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus
outside the United States. Furthermore, you should not consider this prospectus to be an offer or solicitation relating to the
securities if the person making the offer or solicitation is not qualified to do so, or if it is unlawful for you to receive such
an offer or solicitation. You should not assume that the information contained in this prospectus or any free writing prospectus
is accurate as of any date other than the date on the front cover of those documents, or that the information contained in any
document incorporated by reference is accurate as of any date other than the date of the document incorporated by reference, regardless
of the time of delivery of this prospectus or any sale of a security. Our business, financial condition, results of operations
and prospects may have changed since those dates. It is important for you to read and consider all information contained in this
prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein and therein, and any free writing
prospectus prepared by or on behalf of us that we may authorize for use in connection with this offering, in their entirety, before
making an investment decision. You should also read and consider the information in the documents to which we have referred you
in the sections entitled &ldquo;Where You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference&rdquo;
in this prospectus supplement and in the accompanying prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In this prospectus supplement and the accompanying
prospectus, unless the context otherwise requires, references to &ldquo;INmune Bio,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo;
&ldquo;our,&rdquo; or &ldquo;us,&rdquo; in this prospectus refer to INmune Bio, Inc. and its wholly-owned subsidiaries, unless
the context suggests otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>PROSPECTUS SUPPLEMENT SUMMARY</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>This summary highlights certain information
about this offering and selected information contained elsewhere in or incorporated by reference into this prospectus supplement
and the accompanying prospectus. This summary is not complete and does not contain all of the information that you should consider
before deciding whether to invest in our shares of common stock. You should carefully read this entire prospectus supplement and
accompanying prospectus, including the information incorporated herein and therein, including the &ldquo;Risk Factors&rdquo; section
contained in this prospectus supplement and the other documents incorporated by reference into this prospectus supplement. </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We are a clinical-stage
immunotherapy company focused on developing drugs that may reprogram the patient&rsquo;s innate immune system to treat disease.
We believe this may be done by targeting cells of the innate immune system that cause acute and chronic inflammation and are involved
in the immune dysfunction associated with chronic diseases such as cancer, neurodegenerative, metabolic and infectious diseases.
The Company has two therapeutic platforms &ndash; dominant-negative TNF platform (&ldquo;DN-TNF&rdquo;) and the Natural Killer
(&ldquo;NK&rdquo;) platform. The DN-TNF platform neutralizes soluble TNF (&ldquo;sTNF&rdquo;) without affecting trans-membrane
TNF (&ldquo;tmTNF&rdquo;) or the receptors TNFR1 and TNFR2. This unique biologic mechanism differentiates the DN-TNF drugs from
currently approved non-selective TNF inhibitors that inhibit the function of both sTNF and tmTNF. Protecting the function of tmTNF
while neutralizing the function of sTNF is a potent anti-inflammatory drug that does not cause immunosuppression or demyelination.
Currently approved non-selective TNF inhibitors are approved to treat autoimmune disease, however they are contraindicated in patients
with infection, cancer and neurologic diseases because they increase the risk of infection, cancer and demyelinating neurologic
diseases, respectively, because of off-target effects on inhibiting tmTNF. The NK platform targets the dysfunctional natural killer
cells (&ldquo;NK cells&rdquo;) in patients with cancer. NK cells are part of the normal immunologic response to cancer with important
roles in immunosurveillance to prevent cancer and in preventing relapse by clearing residual disease. Residual disease is the cancer
left behind, often undetected, that can grow and cause relapse. The NK cells of cancer patients have the ability to kill cancer
cells but are not effective because cancer cells mutate to evade NK cell immune surveillance. INKmune provides the missing signals
needed to prime NK cells to overcome the immune evasion mutation to allow NK cells to kill the cancer cell. We believe INKmune
is best used to eliminate residual disease after the patient has completed other cancer therapies. Both the DN-TNF platform and
the INKmune platform can be used to treat multiple diseases. The DN-TNF platform will be used as an immunotherapy for the treatment
of cancer, neurodegenerative, metabolic and infectious diseases. INKmune is being developed to treat NK sensitive hematologic malignancies
and solid tumors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We believe our DN-TNF
platform can be used to reverse resistance in immunotherapy, to target glial activation to prevent progression of Alzheimer&rsquo;s
disease (&ldquo;AD&rdquo;), to target neuroinflammation in treatment resistant depression (&ldquo;TRD&rdquo;), to target intestinal
leak and inflammation to treat non-alcoholic steatohepatitis (&ldquo;NASH&rdquo;) and to treat complications of the cytokine storm
associated with COVID-19 infection. The drug is named differently for each indication; INB03, XPro1595, LIVNate and Quellor, respectively,
but it is the same drug product. In each case, we believe neutralizing sTNF is a cornerstone to the treatment of each of these
diseases. As an immunotherapy for cancer, we are using INB03 to neutralize sTNF produced by HER2+ trastuzumab resistant breast
cancers to reverse resistance to therapy. sTNF causes an up-regulation of MUC4 expression that causes steric hindrance of trastuzumab
binding to the HER2/Neu receptor on HER2+ breast cancer cells. Without binding, trastuzumab is not effective. In addition, INB03
changes the immunobiology of the tumor microenvironment by decreasing the number of immunosuppressive myeloid cells, both myeloid
derived suppressor cells and tumor active macrophages, and increasing the number of cytotoxic lymphocytes in the TME. The Company
has completed an open label dose escalation trial in cancer patients with metastatic solid tumors that have failed multiple lines
of therapy. The trial informs the design of the Phase II trial by demonstrating that INB03 was safe and well tolerated, defined
the dose of INB03 to carry into Phase II trials, and demonstrated a pharmacodynamic end-point. A Phase II trial is planned in women
with advanced HER2+ breast cancer with metastasis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Likewise, we believe
the DN-TNF platform can be used to treat selected neurodegenerative diseases. XPro1595 is being used to treat patients with Alzheimer&rsquo;s
disease in a Phase I trial partially funded by a Part-the-Clouds Award from the Alzheimer&rsquo;s Association. XPro1595 targets
activated microglia and astrocytes of the brain that produce sTNF that promotes nerve cell loss and synaptic dysfunction, key elements
in the development of dementia. In animal models, elimination of sTNF prevents nerve cell dysfunction and reverses synaptic pruning.
The Phase I trial in patients with biomarkers of inflammation with AD is enrolling patients. The open label, dose escalation trial
is designed to demonstrate that XPro1595 decreases neuroinflammation in patients with AD. This end-points of the trial are measures
of neuroinflammation and neurodegeneration in blood and cerebral spinal fluid, measures of neuroinflammation by MRI by measuring
white matter free water and breath by measuring volatile organic compounds in exhaled breath and by monitoring neuropsychiatric
symptoms known to be associated with neuroinflammation including depression, apathy, aggression, hallucinations and sleep disorders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In addition, we believe
the DN-TNF platform can be used to treat selected metabolic diseases. LIVNate is being developed to treat NASH. NASH is a pleiotropic
disease caused by a complex mix of metabolic, inflammatory and fibrotic pathophysiology. We believe targeting inflammation caused
by intestinal leak, mesenteric and peripheral fat will prevent lipotoxicity, hepatic stellate cell activation and hepatocyte death
that causes fibrosis and liver dysfunction associated with advanced disease. sTNF is elevated in obesity and is believed to cause
intestinal leak. Intestinal leak combined with cytokines coming from mesenteric fat may dramatically increase the concentration
of inflammatory cytokines in portal blood destined for the liver. The cytokine load contributes to the development of non-alcoholic
fatty liver disease (&ldquo;NAFLD&rdquo;) and progression to NASH. LIVNate, by neutralizing sTNF improves insulin sensitivity,
decreases the inflammation in peripheral and mesenteric fat and may also seal the intestinal leak. This combination prevents development
of NAFLD or NASH in animal models. The Company is planning a Phase II open label randomized study using non-invasive measures to
enroll patients with NASH in a study using a fixed dose of LIVNate delivered as a once a week sub-cutaneous injection.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We also believe the
DN-TNF platform may be used to treat the complications associated with the cytokine storm caused by coronavirus disease 2019 (&ldquo;COVID-19&rdquo;).
Three inflammatory cytokines make up the cytokine storm associated with COVID19 infection &ndash; sTNF, IL-6 and IL-1&beta;. Targeting
sTNF with Quellor may have advantages because IL-6 and IL-1 expression occur after sTNF expression; sTNF promotes endothelial activation
causing expression of proteins that promote trafficking of immune cells from the blood vessel to the tissue and expression of Tissue
Factor that stimulates the coagulopathy that is a prominent pathology of COVID-19 infection. The Company plans a Phase II trial
in patients with symptomatic COVID-19 infection and hypoxia. The goal of the study is to prevent the catastrophic complications
of advanced COVID-19 infection including one or more of the need for mechanical ventilation, new onset of cardiovascular, neurologic
or thromboembolic disease, admission to an intensive care unit or death. The randomized trial will treat patients requiring hospitalization
because of their disease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Effective therapy for
treatment resistant depression (TRD) is a large unmet need. Twenty percent of patients with a Major Depressive Disorder have TRD.
One third of TRD patients have peripheral biomarkers to inflammation (elevated CRP). The role of TNF and anti-TNF therapeutics
was explored in a small open label clinical trial by Prof. Andrew Miller, MD of Emory University demonstrated the patients have
elevated TNF levels and treatment with infliximab treated their depression (Miller, 2011). The Company received a $2.9 million
award from the National Institute of Mental Health (NIMH) to treat TRD with XPro1595. The blinded, randomized Phase II trial will
use a biomarkers of peripheral inflammation to select patients with TRD for enrollment. Patients will be treated for 6 weeks. Primary
end-points include both clinical and neuroimaging measures. The final trial design has is ongoing and discussions with the FDA
are not complete. The Company anticipates receiving authorization to initiate the clinical trial in the second half of 2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We believe that INKmune
improves the ability of the patient&rsquo;s own NK cells to attack their tumor. INKmune interacts with the patient&rsquo;s NK cells
to convert them from inert resting NK cells that ignores the cancer into primed NK cells that kill the cancer cell. INKmune is
a replication incompetent proprietary cell line we have named INB16 that is given to the patient after determining that i) the
patient has adequate NK cells in their circulation and ii) those NK cells are functional when exposed to INKmune in vitro. INKmune
is designed to be given to patients after their immune system has recovered after cytotoxic chemotherapy to target the residual
disease the remains after treatment with cytotoxic therapy.&nbsp; INKmune can be used to treat numerous hematologic malignancies
and solid tumors including leukemia, multiple myeloma, lymphoma, lung, ovary, breast, renal and prostate cancer. The Company plans
Phase I trials using INKmune to treat patients with high risk MDS, a form of leukemia and women with relapsed refractory ovarian.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><I>Shareholder Rights Agreement</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">On December 30, 2020,
the Board of Directors (the &ldquo;Board&rdquo;) of the Company approved and adopted a Rights Agreement, dated as of December 30,
2020, by and between the Company and VStock Transfer, LLC, as rights agent, pursuant to which the Board declared a dividend of
one preferred share purchase right (each, a &ldquo;Right&rdquo;) for each outstanding share of the Company&rsquo;s common stock
held by stockholders as of the close of business on January 11, 2021. When exercisable, each right initially would represent the
right to purchase from the Company one one-thousandth of a share of a newly designated series of preferred stock, Series A Junior
Participating Preferred Stock, par value $0.001 per share, of the Company, at an exercise price of $300.00 per one one-thousandth
of a Series A Junior Participating Preferred Share, subject to adjustment. Subject to various exceptions, the Rights become exercisable
in the event any person (excluding certain exempted or grandfathered persons) becomes the beneficial owner of twenty percent&nbsp;or
more of the Company&rsquo;s common stock without the approval of the Board. The Rights are scheduled to expire on December 30,
2021.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Issuance of shares for cash</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">During January and
February 2021, the Company sold 1,439,480 shares of its common stock for aggregate net proceeds of $28.4 million under a prior
ATM program.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><I>Stock Options</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">During January 2021, the Company granted
198,549 stock options with an exercise price of $24.82 to executives and directors of the Company which vest over 3-4 years. The
fair value of these options was approximately $4.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our principal executive offices are located
at 1200 Prospect Street, Suite 525, La Jolla, California 92037. Our telephone number is (858) 964-3720. We maintain an Internet
website at www.inmunebio.com. The information contained on, connected to or that can be accessed via our website is not part of
this prospectus. We have included our website address in this prospectus as an inactive textual reference only and not as an active
hyperlink.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp; Common stock offered by us</TD>
    <TD STYLE="width: 50%">Shares of our common stock having an aggregate offering price of up to $45,000,000. &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Manner of offering</FONT></TD>
    <TD>&ldquo;At the market offering&rdquo; that may be made from time to time to or through our sales agent, BTIG, LLC. Please see &ldquo;Plan of Distribution&rdquo; on page S-8. &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Use of Proceeds</FONT></TD>
    <TD>We intend to use the net proceeds from this offering for general corporate purposes, including to support research and development, including clinical trials. &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Risk Factors</FONT></TD>
    <TD>See &ldquo;Risk Factors&rdquo; beginning on page S-6 of this prospectus supplement and in the documents incorporated by reference herein for a discussion of factors you should consider carefully before investing in our common stock. &nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Nasdaq Capital Market symbol</FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&ldquo;INMB&rdquo;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><I>An investment in our common stock involves
a high degree of risk. Prior to making a decision about investing in our common stock, you should carefully consider the risk factors
described below and the risk factors discussed in the sections entitled &ldquo;Risk Factors&rdquo; contained in our most recent
Annual Report on Form 10-K, and our other filings with the SEC and incorporated by reference in this prospectus supplement, together
with all of the other information contained in this prospectus supplement. Our business, financial condition and results of operations
could be materially and adversely affected as a result of these risks. This could cause the trading price of our common stock to
decline, resulting in a loss of all or part of your investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to this Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We will have broad discretion in the use of the net proceeds
from this offering and, despite our efforts, we may use the net proceeds in a manner that does not increase the value of your investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We currently intend to use the net proceeds
from this offering for general corporate purposes, including to support research and development, including clinical trials. However,
we have not determined the specific allocation of the net proceeds among these potential uses. Our management will have broad discretion
over the use and investment of the net proceeds from this offering, and, accordingly, investors in this offering will need to rely
upon the judgment of our management with respect to the use of proceeds, with only limited information concerning our specific
intentions. We may use the net proceeds in ways that do not improve our operating results or increase the value of your investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>You may experience immediate and substantial dilution
in the net tangible book value per share of the common stock you purchase in the offering. In addition, we may issue additional
equity or convertible debt securities in the future, which may result in additional dilution to you.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The offering price per share in this offering
may exceed the pro forma net tangible book value per share of our common stock outstanding as of December 31, 2020. Assuming that
we sell an aggregate of 3,144,654 shares of our common stock at a price of $14.31 per share, the last reported sale price of our
common stock on Nasdaq on March 5, 2021, for aggregate gross proceeds of approximately $45,000,000, and after deducting commissions
and estimated aggregate offering expenses payable by us, you will experience immediate dilution of $10.35 per share, representing
the difference between our pro forma as adjusted net tangible book value per share as of December 31, 2020, after giving effect
to this offering and the assumed offering price. See the section titled &ldquo;Dilution&rdquo; below for a more detailed illustration
of the dilution you would incur if you participate in this offering. In addition, to the extent we need to raise additional capital
in the future and we issue additional shares of common stock or securities convertible or exchangeable for our common stock, our
then existing stockholders may experience dilution and the new securities may have rights senior to those of our common stock offered
in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_004"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus supplement, the accompanying
prospectus and the information incorporated by reference herein and therein contain or incorporate forward-looking statements within
the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements reflect
management&rsquo;s beliefs and assumptions. In addition, these forward-looking statements reflect management&rsquo;s current views
with respect to future events or our financial performance, and involve certain known and unknown risks, uncertainties and other
factors, including those identified below, which may cause our or our industry&rsquo;s actual or future results, levels of activity,
performance or achievements to differ materially from those expressed or implied by any forward-looking statements or from historical
results. We intend the forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained
in Section 27A of the Securities Act and Section 21E of the Exchange Act. Forward-looking statements include information concerning
our possible or assumed future results of operations and statements preceded by, followed by, or that include the words &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo;
&ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;potential&rdquo;
or similar expressions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Forward-looking statements are inherently
subject to risks and uncertainties, many of which we cannot predict with accuracy and some of which we might not even anticipate.
Although we believe that the expectations reflected in the forward-looking statements are based upon reasonable assumptions at
the time made, we can give no assurance that the expectations will be achieved. Future events and actual results, financial and
otherwise, may differ materially from the results discussed in the forward-looking statements. Readers are cautioned not to place
undue reliance on these forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The factors described under &ldquo;Risk
Factors&rdquo; in this prospectus supplement and in any documents incorporated by reference herein, and other factors could cause
our or our industry&rsquo;s future results to differ materially from historical results or those anticipated or expressed in any
of our forward-looking statements. We operate in a continually changing business environment, and new risk factors emerge from
time to time. Other unknown or unpredictable factors also could have material adverse effects on our future results, performance
or achievements. We cannot assure you that projected results or events will be achieved or will occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">You should read this prospectus supplement,
the accompanying prospectus and the information incorporated by reference herein and therein completely and with the understanding
that our actual future results may be materially different from what we expect. Any forward-looking statement speaks only as of
the date of this prospectus supplement. We do not assume any obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may issue and sell shares of our common
stock having aggregate gross sales proceeds of up to $45,000,000 from time to time. Because there is no minimum offering amount
required as a condition to close this offering, the actual total public offering amount, commissions and proceeds to us, if any,
are not determinable at this time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will retain broad discretion over the
use of the net proceeds from the sale of the securities offered hereby. We currently intend to use the net proceeds from this offering
for general corporate purposes, including to support research and development, including clinical trials. The precise amount and
timing of the application of such proceeds will depend upon our funding requirements and the availability and cost of other capital.
As of the date of this prospectus supplement, we cannot specify with certainty all of the particular uses for the net proceeds
that we will have from the sale of the shares of our common stock. Pending the use of the net proceeds from this offering, if any,
we may invest the net proceeds in investment grade, short-term interest-bearing obligations, such as money-market funds, certificates
of deposit, or direct or guaranteed obligations of the United States government, or hold the net proceeds as cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>DILUTION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you purchase shares of our common stock
in this offering, your interest will be diluted to the extent of the difference between the public offering price per share and
the net tangible book value per share of our common stock after this offering. We calculate net tangible book value per share by
dividing our net tangible assets (tangible assets less total liabilities) by the number of shares of our common stock issued and
outstanding as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our historical net tangible book value at
December 31, 2020 was $22,239,388 or approximately $1.65 per share of our common stock. After giving effect to the sale of our
common stock in the aggregate amount of approximately $45,000,000 in this offering, at an assumed offering price of $14.31 per
share, the last reported sale price of our common stock on Nasdaq on March 5, 2020, and after deducting estimated offering expenses
and commissions payable by us, our adjusted net tangible book value as of December 31, 2020 would have been approximately $65,799,388,
or approximately $3.96 per share of our common stock. This represents an immediate increase in the net tangible book value of $2.31
per share of our common stock to our existing stockholders and an immediate dilution in net tangible book value of approximately
$10.35 per share of our common stock to new investors. The following table illustrates per share dilution:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD STYLE="width: 90%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assumed public offering price per share</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 7%; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.31</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net tangible book value per share as of December 31, 2020</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.65</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase in net tangible book value per share attributable to this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.31</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjusted net tangible book value per share as of December 31, 2020, after giving effect to this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.96</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dilution per share to new investors purchasing shares in this offering</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The table above assumes for illustrative
purposes that an aggregate of 3,144,654 shares of our common stock are sold at a price of $14.31 per share, the last reported sale
price of our common stock on Nasdaq on March 5, 2021, for aggregate gross proceeds of approximately $45,000,000. The shares sold
in this offering, if any, will be sold from time to time at various prices. An increase of $2.00 per share in the price at which
the shares are sold from the assumed offering price of $14.31 per share shown in the table above, assuming all of our common stock
in the aggregate amount of $45,000,000 is sold at that price, would increase our adjusted net tangible book value per share after
the offering to $4.05 per share and would increase the dilution in net tangible book value per share to new investors in this offering
to $12.26 per share, after deducting estimated offering expenses and commissions payable by us. A decrease of $2.00 per share in
the price at which the shares are sold from the assumed offering price of $14.31 per share shown in the table above, assuming all
of our common stock in the aggregate amount of $45,000,000 is sold at that price, would decrease our adjusted net tangible book
value per share after the offering to $3.84 per share and would decrease the dilution in net tangible book value per share to new
investors in this offering to $8.47 per share, after deducting estimated offering expenses and commissions payable by us. This
information is supplied for illustrative purposes only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information above is based on 13,481,283
shares of our common stock outstanding as of December 31, 2020, and excludes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,457,000 shares of our common stock issuable upon the exercise of stock options outstanding at December 31, 2020, at a weighted average exercise price of $5.82 per share (2,232,910 of which are exercisable at a weighted average exercise price of $6.69 per share);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,955,922 shares of our common stock issuable upon the exercise of warrants outstanding at December 31, 2020, at a weighted average exercise price of $5.31 per share;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: left; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">214,525 additional shares of our common stock available for future issuance as of December 31, 2020, under our stock incentive plans (the Company granted certain officers and directors 198,549 stock options exercisable into common stock at an exercise price of $24.82 under our stock incentive plans during January 2021);</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the above discussion and table
do not include the up to approximately $29.0 million worth of shares of our common stock that remained available for sale at December
31, 2020, under an at market issuance sales agreement with BTIG, dated as of April 16, 2020, as amended August 18, 2020, which
we refer to as the Prior Sales Agreement. Between January 1, 2021 and the date of this prospectus supplement, we sold an aggregate
of 1,439,480 shares of our common stock for gross proceeds of approximately $29.0 million under the Prior Sales Agreement, and
as of the date of this prospectus supplement, no shares remained available for sale under the Prior Sales Agreement.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">To the extent that outstanding options or
warrants are exercised, or we issue other shares, investors purchasing shares in this offering could experience further dilution.
In addition, to the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance
of those securities could result in further dilution to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have entered into the sales agreement
with BTIG under which we may issue and sell shares of our common stock having an aggregate offering price of up to $45,000,000
from time to time through BTIG, acting as our sales agent. The sales of our common stock, if any, under this prospectus supplement
will be made at market prices by any method deemed to be an &ldquo;at the market offering&rdquo; as defined in Rule 415(a)(4) under
the Securities Act, including sales made directly on The Nasdaq Capital Market, on any other existing trading market for our common
stock, or to or through a market maker.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Each time that we wish to issue and sell
shares of our common stock under the sales agreement, we will provide BTIG with a placement notice describing the amount of shares
to be sold, the time period during which sales are requested to be made, any limitation on the amount of shares of common stock
that may be sold in any single day, any minimum price below which sales may not be made or any minimum price requested for sales
in a given time period and any other instructions relevant to such requested sales. Upon receipt of a placement notice, BTIG, acting
as our sales agent, will use commercially reasonable efforts, consistent with its normal trading and sales practices and applicable
state and federal laws, rules and regulations and the rules of the Nasdaq Capital Market, to sell shares of our common stock under
the terms and subject to the conditions of the placement notice and the sales agreement. We or BTIG may suspend the offering of
common stock pursuant to a placement notice upon notice and subject to other conditions. BTIG, in its sole discretion, may decline
to accept any placement notice.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">BTIG will provide written confirmation to
us no later than the opening of the trading day on the Nasdaq Capital Market following the trading day on which shares of our common
stock are sold through BTIG as sales agent under the sales agreement. Each confirmation will include the number of shares sold
on the preceding day, the net proceeds to us and the commissions payable by us to BTIG in connection with the sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Settlement for sales of common stock under
the sales agreement will occur on the second trading day following the date on which such sales are made (or on such other date
as is industry practice for regular-way trading), unless otherwise specified in the applicable placement notice, in return for
payment of the net proceeds to us. There are no arrangements to place any of the proceeds of this offering in an escrow, trust
or similar account. Sales of our common stock as contemplated in this prospectus supplement will be settled through the facilities
of The Depository Trust Company or by such other means as we and BTIG may agree upon.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We will pay BTIG commissions for its services
in acting as our sales agent in the sale of our common stock pursuant to the sales agreement. BTIG will be entitled to compensation
at a fixed commission rate of 3.0% of the gross proceeds from the sale of our common stock on our behalf pursuant to the sales
agreement. We also have agreed to reimburse BTIG for its reasonable out-of-pocket expenses, including the fees and disbursements
of BTIG&rsquo;s counsel, incurred in connection with entering into the sales agreement, in an amount not to exceed $50,000, plus
additional amounts, not to exceed $7,500 per calendar quarter during which shares of our common stock have been sold under the
sales agreement, to reimburse BTIG for additional out-of-pocket expenses it may incur after the date of this prospectus supplement
in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We estimate that the total expenses for
this offering, excluding compensation payable to BTIG and certain expenses reimbursable to BTIG under the terms of the sales agreement,
will be approximately $40,000. <FONT STYLE="background-color: white">The remaining sales proceeds, after deducting any expenses
payable by us and any transaction fees imposed by any governmental, regulatory, or self-regulatory organization in connection with
the sales, will equal our net proceeds for the sale of such common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because there are no minimum sale requirements
as a condition to this offering, the actual total public offering price, commissions and net proceeds to us, if any, are not determinable
at this time. The actual dollar amount and number of shares of common stock we sell through this prospectus supplement will be
dependent, among other things, on market conditions and our capital raising requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">We
will report at least quarterly the number of shares of common stock sold through BTIG under the sales agreement, the net proceeds
to us and the compensation paid by us to BTIG in connection with the sales of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In connection with the sale of the common
stock on our behalf, BTIG will be deemed to be an &ldquo;underwriter&rdquo; within the meaning of the Securities Act, and the compensation
of BTIG will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution
to BTIG against certain civil liabilities, including liabilities under the Securities Act or the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">BTIG will not engage in any market making
activities involving our common stock while the offering is ongoing under this prospectus supplement if such activity would be
prohibited under Regulation M or other anti-manipulation rules under the Securities Act. <FONT STYLE="background-color: white">As
our sales agent, BTIG will not engage in any transactions that stabilizes our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The offering pursuant to the sales agreement
will terminate upon the earlier of (i) the sale of all shares of common stock subject to the sales agreement and (ii) termination
of the sales agreement as permitted therein. We may terminate the sales agreement in our sole discretion at any time by giving
10 days&rsquo; prior notice to BTIG. BTIG may terminate the sales agreement under the circumstances specified in the sales agreement
and in its sole discretion at any time by giving 10 days&rsquo; prior notice to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The sales agreement has been filed as an
exhibit to a current report on Form 8-K that we filed with the SEC in connection with this offering and is incorporated into this
prospectus supplement by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">BTIG has provided, and BTIG and/or its affiliates
may in the future provide, various investment banking and other financial services for us, for which BTIG has received, and BTIG
and/or its affiliates may in the future receive, customary fees and commissions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The validity of the securities offered by
this prospectus will be passed upon by Sichenzia Ross Ference LLP, New York, New York. Certain matters will be passed upon for
BTIG by Dorsey &amp; Whitney LLP, New York, New York.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The consolidated financial statements of
INmune Bio Inc. as of and for the years ended December 31, 2020 and 2019 appearing in INmune Bio Inc.&rsquo;s Annual Report on
Form 10-K for the year ended December 31, 2020, have been audited by Marcum LLP, as set forth in its report thereon, included therein,
and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon
such report given on the authority of such firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our SEC filings are available to the public at the SEC&rsquo;s web site at
http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We make available free of charge on or through
our Internet website www.inmunebio.com, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form
8&ndash;K, and amendments to those reports filed or furnished pursuant to Section 13(a), 14 or 15(d) of the Exchange Act as soon
as reasonably practicable after we electronically file the material with, or furnish it to, the SEC. The references to&nbsp;www.inmunebio.com&nbsp;in
this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein or therein are inactive
textual references only, and the information found on our internet website is not incorporated by reference into, and should not
be considered part of, this prospectus supplement, the accompanying base shelf prospectus or the documents incorporated by reference
herein or therein. Investors should not rely on any such information in deciding whether to invest in our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_011"></A>INFORMATION INCORPORATED BY REFERENCE
</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The SEC allows us to incorporate by reference
information contained in documents we file with it, which means that we can disclose important information to you by referring
you to those documents already on file with the SEC that contain that information. The information incorporated by reference is
considered to be part of this prospectus supplement, and later information that we file with the SEC will automatically update
and supersede this information. We incorporate by reference the documents listed below and any future information filed (rather
than furnished) with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, between the date of this prospectus
supplement and the termination of the offering of the securities covered by this prospectus supplement, provided, however, that
we are not incorporating any information furnished under any of Item 2.02 or Item 7.01 of any Current Report on Form 8-K (and exhibits
filed on such form that are related to such items):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390021013456/f10k2020_inmunebioinc.htm">Form 10-K</A> for the year ended December 31, 2020, filed with the SEC on March 4, 2021;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our Current Reports on Form 8-K filed with the
    SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390021000217/ea132661-8ka1_inmune.htm">January 4, 2021</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390021002668/ea133517-8k_inmunebio.htm">January 19, 2021</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390021003327/ea133643-8k_inmunebio.htm">January 21, 2021</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390021003480/ea133728-8k_inmunebio.htm">January 21, 2021</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390021004031/ea133876-8k_inmunebio.htm">January 25, 2021</A>; <A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390021012742/ea136834-8k_inmunebio.htm">March 2, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390021013731/ea137109-8k_immunebio.htm">March 5, 2021</A>
    and <A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390021014649/ea137374-8k_inmunebioinc.htm">March 11, 2021</A>;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The description of our common stock contained in our Registration Statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000164033419000136/inmune_8a12b.htm">Form 8-A</A>&nbsp;filed with the SEC on February 1, 2019 (File No. 001-38793), including any amendment or report filed for the purpose of updating such description. In addition, a Form 8-A filed on December 30, 2020, contains a description of certain rights attributable to the common stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">The information about us contained in this
prospectus should be read together with the information in the documents incorporated by reference. You may request a copy of any
or all of these filings, at no cost, by writing or telephoning us at: David Moss, INmune Bio Inc., 1200 Prospect Street, Suite
525, La Jolla, CA 92037, telephone number (858) 964-3720.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$100,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INMUNE BIO, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Units</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may from time to time, in one or more
offerings at prices and on terms that we will determine at the time of each offering, sell common stock, preferred stock, warrants,
or a combination of these securities, or units, for an aggregate initial offering price of up to $100,000,000. This prospectus
describes the general manner in which our securities may be offered using this prospectus. Each time we offer and sell securities,
we will provide you with a prospectus supplement that will contain specific information about the terms of that offering. Any prospectus
supplement may also add, update, or change information contained in this prospectus. You should carefully read this prospectus
and the applicable prospectus supplement as well as the documents incorporated or deemed to be incorporated by reference in this
prospectus before you purchase any of the securities offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="background-color: white">We
are an &ldquo;emerging growth company&rdquo; under applicable Securities and Exchange Commission, or the SEC, rules and, as such,
have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings.</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus may not be used to offer
and sell securities unless accompanied by a prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is currently traded on
the NASDAQ Capital Market under the symbol &ldquo;INMB.&rdquo; On March 23, 2020, the last reported sales price for our common
stock was $2.41 per share. The applicable prospectus supplement will contain information, where applicable, as to any other listing
of the securities on the NASDAQ Capital Market or any other securities market or exchange covered by the prospectus supplement.
Prospective purchasers of our securities are urged to obtain current information as to the market prices of our securities, where
applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may offer the securities directly or
through agents or to or through underwriters or dealers. If any agents or underwriters are involved in the sale of the securities
their names, and any applicable purchase price, fee, commission or discount arrangement between or among them, will be set forth,
or will be calculable from the information set forth, in an accompanying prospectus supplement. We can sell the securities through
agents, underwriters or dealers only with delivery of a prospectus supplement describing the method and terms of the offering of
such securities. See &ldquo;Plan of Distribution.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The aggregate market value of our outstanding
common stock held by non-affiliates was approximately $20,034,182 which was calculated based on 3,787,180 shares of outstanding
common stock held by non-affiliates as of March 24, 2020, and a price per share of $5.29, the closing price of our common stock
on February 20, 2020. Pursuant to General Instruction I.B.6 of Form&nbsp;S-3, in no event will we sell securities pursuant to this
registration statement with a value more than one-third of the aggregate market value of our common stock held by non-affiliates
in any 12-month period, so long as the aggregate market value of our common stock held by non-affiliates is less than $75.0 million.
In the event that subsequent to the effective date of this registration statement, the aggregate market value of our outstanding
common stock held by non-affiliates equals or exceeds $75.0 million, then the one-third limitation on sales shall not apply to
additional sales made pursuant to this registration statement. As of the date of this prospectus, <FONT STYLE="background-color: white">we
have not offered any securities pursuant to General Instruction I.B.6 of </FONT>Form&nbsp;S-3&nbsp;during <FONT STYLE="background-color: white">the
12 calendar months prior to and including the date of this prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>The securities offered by this prospectus
involve a high degree of risk. See &ldquo;Risk Factors&rdquo; beginning on page 5, in addition to Risk Factors contained in the
applicable prospectus supplement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful
or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">This prospectus is dated April 2, 2020</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD STYLE="width: 91%">&nbsp;</TD>
    <TD STYLE="width: 9%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#b_001"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#b_002"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#b_003"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">ABOUT INMUNE BIO</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#b_004"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">RISK FACTORS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#b_005"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">USE OF PROCEEDS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#b_006"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF CAPITAL STOCK</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#b_007"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF WARRANTS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#b_008"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">DESCRIPTION OF UNITS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#b_009"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">PLAN OF DISTRIBUTION</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#b_011"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EXPERTS</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF">
    <TD><A HREF="#b_012"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white">
    <TD><A HREF="#b_013"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>You should rely only on the information
contained or incorporated by reference in this prospectus or any prospectus supplement. We have not authorized anyone to provide
you with information different from that contained or incorporated by reference into this prospectus. If any person does provide
you with information that differs from what is contained or incorporated by reference in this prospectus, you should not rely on
it. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this
prospectus. You should assume that the information contained in this prospectus or any prospectus supplement is accurate only as
of the date on the front of the document and that any information contained in any document we have incorporated by reference is
accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus or
any prospectus supplement or any sale of a security. These documents are not an offer to sell or a solicitation of an offer to
buy these securities in any circumstances under which the offer or solicitation is unlawful.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus is part of a registration
statement that we filed with the Securities and Exchange Commission, or SEC, using a &ldquo;shelf&rdquo; registration process.
Under this shelf registration process, we may sell any combination of the securities described in this prospectus in one of more
offerings up to a total dollar amount of proceeds of $100,000,000. This prospectus describes the general manner in which our securities
may be offered by this prospectus. Each time we sell securities, we will provide a prospectus supplement that will contain specific
information about the terms of that offering. The prospectus supplement may also add, update or change information contained in
this prospectus or in documents incorporated by reference in this prospectus. The prospectus supplement that contains specific
information about the terms of the securities being offered may also include a discussion of certain U.S. Federal income tax consequences
and any risk factors or other special considerations applicable to those securities. To the extent that any statement that we make
in a prospectus supplement is inconsistent with statements made in this prospectus or in documents incorporated by reference in
this prospectus, you should rely on the information in the prospectus supplement. You should carefully read both this prospectus
and any prospectus supplement together with the additional information described under &ldquo;Where You Can Find More Information&rdquo;
before buying any securities in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The terms &ldquo;INmune Bio,&rdquo; the
&ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;our,&rdquo; or &ldquo;us,&rdquo; in this prospectus refer to INmune Bio, Inc. and
its wholly-owned subsidiaries, unless the context suggests otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_002"></A>CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING
STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus and the documents and information
incorporated by reference in this prospectus include forward-looking statements within the meaning of Section 27A of the Securities
Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange
Act. These statements are based on our management&rsquo;s beliefs and assumptions and on information currently available to our
management. All statements, other than statements of historical fact, included regarding our strategy, future operations, financial
position, future revenues, projected costs, plans, prospects and objectives are forward-looking statements. Words such as &ldquo;expect,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;believe,&rdquo; &ldquo;seek,&rdquo; &ldquo;estimate,&rdquo;
&ldquo;think,&rdquo; &ldquo;may,&rdquo; &ldquo;could,&rdquo; &ldquo;will,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;continue,&rdquo;
&ldquo;potential,&rdquo; &ldquo;likely,&rdquo; &ldquo;opportunity&rdquo; and similar expressions or variations of such words are
intended to identify forward-looking statements but are not the exclusive means of identifying forward-looking statements. Examples
of our forward-looking statements include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to raise funds for general corporate purposes and operations, including our research activities and clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to recruit qualified management and technical personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the success of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our ability to obtain and maintain required regulatory approvals for our trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our expectations regarding the use of our existing cash and the expected net proceeds of this offering;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the other factors discussed in the &ldquo;Risk Factors&rdquo; section and elsewhere in this prospectus.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Because forward-looking statements are inherently
subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you
should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in
our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in
the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge
from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable
law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new
information, future events, changed circumstances or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus and the documents incorporated
herein by reference also refer to estimates and other statistical data made by independent parties and by us relating to market
size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned
not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future performance and the
future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_003"></A>ABOUT INMUNE BIO INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are a clinical-stage immunotherapy company
focused on reprogramming the patient&rsquo;s innate immune system to treat disease. We do this by targeting four key cells of the
innate immune system, natural killer, or NK cells, and myeloid derived suppressor cells, or MDSC, hepatic stellate cells of the
liver, or HSC, and microglial cells of the central nervous system. NK cells are the body&rsquo;s first line of defense due to their
innate ability to rapidly seek and destroy abnormal cells, such as cancer or virally-infected cells, without prior exposure or
activation by other support molecules required to activate adaptive immune cells such as T-cells. NK cells play a key role in the
immune-surveillance that prevents people from getting cancer and in eliminating residual disease which may cause people to relapse
after cytotoxic therapy. MDSC are myeloid cells produced in the bone marrow, take up residence in the tumor microenvironment, the
tissue associated with the cancerous cells, to protect the tumor from immunological attack by the patient&rsquo;s immune system.
MDSC play a critical role in making the cancer resistant to immunotherapy such as currently approved checkpoint inhibitors. Microglial
cells are the primary immune cells of the central nervous system responsible for protecting the neural unit of microglia, astrocytes,
oligodendrocytes and neurons from infection. In the setting of chronic inflammation, microglial cells become activated and cause
dysfunction of the other three cells types in the neural unit resulting in neurodegenerative and neuropsychiatric diseases. Hepatic
stellate cells are immunologically active cells that are part of the liver architecture that support hepatocyte function in health
and disease. INB03, LivNate and XPro1595 are the identical drug used in different therapeutic arenas. INB03 is the name of the
drug for cancer targeted applications. XPro1595 in the name of the drug for neurology and psychiatric indications. LivNate is the
name of the drug for treatment of liver diseases.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp; &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe INKmune, our NK cell directed
therapy, and INB03, our MDSC directed therapy, and XPro1595, our microglial directed therapy and LivNate, our HSC directed therapy
offer unique strategies to improve the response of patients&rsquo; innate immune system to their cancer, neurologic and liver disease
respectively. These therapies will use a precision medicine approach to select patients who will benefit from the therapy and monitor
the response to the therapy. For oncology, neither INB03 nor INKmune therapy is cancer specific. The decision to use either INKmune
or INB03 as part of cancer therapies, or with each other, depends on immunologic parameters that can be tested in patients before
treatment. The type of cancer is not important. This means that both therapies can be used to treat patients with a variety of
hematologic malignancies and solid tumors that have the immunologic profile needed to respond. Put simply, we are treating the
immune system to attack the patients&rsquo; cancer, not targeting the patient&rsquo;s cancer directly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We believe that INKmune improves the ability
of the patient&rsquo;s own NK cells to attack their tumor. INKmune itself will not kill cancer cells. INKmune interacts with the
patient&rsquo;s NK cells to convert them from inert resting NK cells that ignores the cancer into primed NK cells that kill the
cancer cell. INKmune is a replication incompetent proprietary cell line we have named INB16 that is given to the patient after
determining that i) the patient has adequate NK cells in their circulation and ii) those NK cells are functional when exposed to
INKmune in vitro. INKmune is designed to be given to patients after their immune system has recovered after cytotoxic chemotherapy
to target the residual disease the remains after treatment with cytotoxic therapy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Likewise, we believe XPro1595, our microglial
directed therapy, offers a unique strategy to decrease neuroinflammation, a key pathophysiology in neurodegenerative and neuropsychiatric
diseases. XPro1595 will use a precision medicine approach to select patients who will benefit from the therapy and monitor the
response to the therapy. The therapy is not diagnosis specific but will be used in patients who have biomarkers of neuroinflammation.
Our initial program with XPro1595 will be treating patients with Alzheimer&rsquo;s disease with biomarkers inflammation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Likewise, we believe LivNate, our HSC directed
therapy, offers a unique strategy to treat NASH by decreasing peripheral , regional and local inflammatory cycles that results
in hepatocyte ballooning and death, hepatitis and fibrosis, the core pathophysiology of many inflammatory liver diseases. Our initial
program with LivNate will be treating patients with NASH.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We reported a net loss of $7,678,313 and
$12,440,023 for the years ended December 31, 2019 and 2018, respectively. We have an accumulated deficit of $21,276,181 as of December
31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Implications of Being an Emerging Growth Company and a Smaller
Reporting Company </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As a company with less than $1.07&nbsp;billion
in revenue during our last fiscal year, we qualify as an &ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our
Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of reduced reporting requirements
that are otherwise applicable to public companies. These provisions include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">being permitted to present only two years of audited financial statements and two years of related Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">reduced disclosure obligations regarding executive compensation in periodic reports, proxy statements and registration statements; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may take advantage of these provisions
until the last day of our fiscal year following the fifth anniversary of our initial public offering. However, if certain events
occur prior to the end of such five-year period, including if we become a &ldquo;large accelerated filer,&rdquo; our annual gross
revenue exceeds $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of non-convertible debt in any three-year period, we
will cease to be an emerging growth company prior to the end of such five-year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We have elected to take advantage of certain
of the reduced disclosure obligations in this prospectus and may elect to take advantage of other reduced reporting requirements
in future filings. As a result, the information that we provide to our stockholders may be different from what you might receive
from other public reporting companies in which you hold equity interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, under the JOBS Act, emerging
growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are also a &ldquo;smaller reporting company,&rdquo;
as that term is defined in Rule&nbsp;12b-2 under the Exchange Act. As a result, many of the same exemptions from reporting requirements
available to us as an emerging growth company are also available to us as a smaller reporting company, including not being required
to comply with the auditor attestation requirements of Section&nbsp;404(b) of the Sarbanes-Oxley Act and reduced disclosure obligations
regarding executive compensation. To the extent that we continue to qualify as a smaller reporting company, after we cease to qualify
as an emerging growth company, those exemptions may continue to be available to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our principal executive offices are located
at 1200 Prospect Street, Suite 525, La Jolla, California 92037. Our telephone number is (858) 964-3720. We maintain an Internet
website at www.inmunebio.com. The information contained on, connected to or that can be accessed via our website is not part of
this prospectus. We have included our website address in this prospectus as an inactive textual reference only and not as an active
hyperlink.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_004"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Investing in our securities involves a high
degree of risk. Before making an investment decision, you should consider carefully the risks, uncertainties and other factors
described in our most recent Annual Report on Form 10-K, as supplemented and updated by subsequent quarterly reports on Form 10-Q
and current reports on Form 8-K that we have filed or will file with the SEC, which are incorporated by reference into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our business, affairs,
prospects, assets, financial condition, results of operations and cash flows could be materially and adversely affected by these
risks. For more information about our SEC filings, please see &ldquo;Where You Can Find More Information&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_005"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless otherwise indicated in a prospectus
supplement, we intend to use the net proceeds from the sale of the securities under this prospectus for general corporate purposes,
including to support research and development, including clinical trials, and general corporate purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_006"></A>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following description of our capital
stock, together with any additional information we include in any applicable prospectus supplement or any related free writing
prospectus, summarizes the material terms and provisions of our common stock and the preferred stock that we may offer under this
prospectus. While the terms we have summarized below will apply generally to any future common stock or preferred stock that we
may offer, we will describe the particular terms of any class or series of these securities in more detail in the applicable prospectus
supplement. For the complete terms of our common stock and preferred stock, please refer to our articles of incorporation and our
bylaws that are incorporated by reference into the registration statement of which this prospectus is a part. The summary below
and that contained in any applicable prospectus supplement or any related free writing prospectus are qualified in their entirety
by reference to our articles of incorporation and our bylaws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are authorized to issue 200,000,000 shares
of common stock, $0.001 par value per share. &nbsp;As of the date of this prospectus, there are 10,746,948 shares of common stock
issued and outstanding. The outstanding shares of common stock are validly issued, fully paid and nonassessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Holders of common stock are entitled to
one vote for each share on all matters submitted to a stockholder vote. Holders of common stock do not have cumulative voting rights.
Therefore, holders of a majority of the shares of common stock voting for the election of directors can elect all of the directors.
Holders of common stock representing a majority of the voting power of our capital stock issued, outstanding and entitled to vote,
represented in person or by proxy, are necessary to constitute a quorum at any meeting of stockholders. A vote by the holders of
a majority of the Company&rsquo;s outstanding shares is required to effectuate certain fundamental corporate changes such as liquidation,
merger or an amendment to the Company&rsquo;s certificate of incorporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Holders of common stock are entitled to
share in all dividends that our Board of Directors, in its discretion, declares from legally available funds. In the event of a
liquidation, dissolution or winding up, each outstanding share entitles its holder to participate pro rata in all assets that remain
after payment of liabilities and after providing for each class of stock, if any, having preference over the common stock. The
common stock has no pre-emptive, subscription or conversion rights and there are no redemption provisions applicable to the common
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We are authorized to issue up to 10,000,000
shares of preferred stock, par value $0.001 per share, from time to time in one or more series. As of the date of this prospectus,
there were no shares of our preferred stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our articles of incorporation authorizes
our Board of Directors to issue preferred stock from time to time with such designations, preferences, conversion or other rights,
voting powers, restrictions, dividends or limitations as to dividends or other distributions, qualifications or terms or conditions
of redemption as shall be determined by the Board of Directors for each class or series of stock. Preferred stock is available
for possible future financings or acquisitions and for general corporate purposes without further authorization of stockholders
unless such authorization is required by applicable law, the rules of the NASDAQ Capital Market or other securities exchange or
market on which our stock is then listed or admitted to trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our Board of Directors may authorize the
issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the
holders of common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions
and other corporate purposes could, under some circumstances, have the effect of delaying, deferring or preventing a change-in-control
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">A prospectus supplement relating to any
series of preferred stock being offered will include specific terms relating to the offering. Such prospectus supplement will include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the title and stated or par value of the preferred stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the number of shares of the preferred stock offered, the liquidation preference per share and the offering price of the preferred stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the dividend rate(s), period(s) and/or payment date(s) or method(s) of calculation thereof applicable to the preferred stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">whether dividends shall be cumulative or non-cumulative and, if cumulative, the date from which dividends on the preferred stock shall accumulate;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the provisions for a sinking fund, if any, for the preferred stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any voting rights of the preferred stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the provisions for redemption, if applicable, of the preferred stock;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any listing of the preferred stock on any securities exchange;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms and conditions, if applicable, upon which the preferred stock will be convertible into our common stock, including the conversion price or the manner of calculating the conversion price and conversion period;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if appropriate, a discussion of Federal income tax consequences applicable to the preferred stock; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&#9679;</B></FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other specific terms, preferences, rights, limitations or restrictions of the preferred stock.&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The terms, if any, on which the preferred
stock may be convertible into or exchangeable for our common stock will also be stated in the preferred stock prospectus supplement.
The terms will include provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option,
and may include provisions pursuant to which the number of shares of our common stock to be received by the holders of preferred
stock would be subject to adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The transfer agent for our common stock
is VStock Transfer, LLC. The transfer agent&rsquo;s address is 18 Lafayette Place, Woodmere, New York 11598.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Our common stock is currently traded on
the NASDAQ Capital Market under the symbol &ldquo;INMB&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_007"></A>DESCRIPTION OF WARRANTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may issue warrants for the purchase of
preferred stock or common stock. Warrants may be issued independently or together with any preferred stock or common stock, and
may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement
to be entered into between a warrant agent specified in the agreement and us. The warrant agent will act solely as our agent in
connection with the warrants of that series and will not assume any obligation or relationship of agency or trust for or with any
holders or beneficial owners of warrants. This summary of some provisions of the securities warrants is not complete. You should
refer to the securities warrant agreement, including the forms of securities warrant certificate representing the securities warrants,
relating to the specific securities warrants being offered for the complete terms of the securities warrant agreement and the securities
warrants. The securities warrant agreement, together with the terms of the securities warrant certificate and securities warrants,
will be filed with the SEC in connection with the offering of the specific warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The applicable prospectus supplement will
describe the following terms, where applicable, of the warrants in respect of which this prospectus is being delivered:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the title of the warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the aggregate number of the warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the price or prices at which the warrants will be issued;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the designation, amount and terms of the offered securities purchasable upon exercise of the warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if applicable, the date on and after which the warrants and the offered securities purchasable upon exercise of the warrants will be separately transferable;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of the securities purchasable upon exercise of such warrants and the procedures and conditions relating to the exercise of such warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any provisions for adjustment of the number or amount of securities receivable upon exercise of the warrants or the exercise price of the warrants;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the price or prices at which and currency or currencies in which the offered securities purchasable upon exercise of the warrants may be purchased;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the date on which the right to exercise the warrants shall commence and the date on which the right shall expire;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the minimum or maximum amount of the warrants that may be exercised at any one time;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">information with respect to book-entry procedures, if any;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">if appropriate, a discussion of Federal income tax consequences; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any other material terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Warrants for the purchase of common stock
or preferred stock will be offered and exercisable for U.S. dollars only. Warrants will be issued in registered form only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Upon receipt of payment and the warrant
certificate properly completed and duly executed at the corporate trust office of the warrant agent or any other office indicated
in the applicable prospectus supplement, we will, as soon as practicable, forward the purchased securities. If less than all of
the warrants represented by the warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Prior to the exercise of any securities
warrants to purchase preferred stock or common stock, holders of the warrants will not have any of the rights of holders of the
common stock or preferred stock purchasable upon exercise, including in the case of securities warrants for the purchase of common
stock or preferred stock, the right to vote or to receive any payments of dividends on the preferred stock or common stock purchasable
upon exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_008"></A>DESCRIPTION OF UNITS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As specified in the applicable prospectus
supplement, we may issue units consisting of shares of common stock, shares of preferred stock or warrants or any combination of
such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The applicable prospectus supplement will
specify the following terms of any units in respect of which this prospectus is being delivered:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of the units and of any of the common stock, preferred stock and warrants comprising the units, including whether and under what circumstances the securities comprising the units may be traded separately;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a description of the terms of any unit agreement governing the units; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a description of the provisions for the payment, settlement, transfer or exchange of the units.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_009"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may sell the securities offered through
this prospectus (i)&nbsp;to or through underwriters or dealers, (ii)&nbsp;directly to purchasers, including our affiliates, (iii)&nbsp;through
agents, or (iv) through a combination of any these methods. The securities may be distributed at a fixed price or prices, which
may be changed, market prices prevailing at the time of sale, prices related to the prevailing market prices, or negotiated prices.
The prospectus supplement will include the following information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the terms of the offering;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the names of any underwriters or agents;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the name or names of any managing underwriter or underwriters;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the purchase price of the securities;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any over-allotment options under which underwriters may purchase additional securities from us;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the net proceeds from the sale of the securities</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any delayed delivery arrangements</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any underwriting discounts, commissions and other items constituting underwriters&rsquo; compensation;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any initial public offering price;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any discounts or concessions allowed or reallowed or paid to dealers;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any commissions paid to agents; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any securities exchange or market on which the securities may be listed.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Sale Through Underwriters or Dealers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Only underwriters named in the prospectus
supplement are underwriters of the securities offered by the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If underwriters are used in the sale, the
underwriters will acquire the securities for their own account, including through underwriting, purchase, security lending or repurchase
agreements with us. The underwriters may resell the securities from time to time in one or more transactions, including negotiated
transactions. Underwriters may sell the securities in order to facilitate transactions in any of our other securities (described
in this prospectus or otherwise), including other public or private transactions and short sales. Underwriters may offer securities
to the public either through underwriting syndicates represented by one or more managing underwriters or directly by one or more
firms acting as underwriters. Unless otherwise indicated in the prospectus supplement, the obligations of the underwriters to purchase
the securities will be subject to certain conditions, and the underwriters will be obligated to purchase all the offered securities
if they purchase any of them. The underwriters may change from time to time any initial public offering price and any discounts
or concessions allowed or reallowed or paid to dealers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If dealers are used in the sale of securities
offered through this prospectus, we will sell the securities to them as principals. They may then resell those securities to the
public at varying prices determined by the dealers at the time of resale. The prospectus supplement will include the names of the
dealers and the terms of the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Direct Sales and Sales Through Agents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may sell the securities offered through
this prospectus directly. In this case, no underwriters or agents would be involved. Such securities may also be sold through agents
designated from time to time. The prospectus supplement will name any agent involved in the offer or sale of the offered securities
and will describe any commissions payable to the agent. Unless otherwise indicated in the prospectus supplement, any agent will
agree to use its reasonable best efforts to solicit purchases for the period of its appointment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We may sell the securities directly to institutional
investors or others who may be deemed to be underwriters within the meaning of the Securities Act with respect to any sale of those
securities. The terms of any such sales will be described in the prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Delayed Delivery Contracts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the prospectus supplement indicates,
we may authorize agents, underwriters or dealers to solicit offers from certain types of institutions to purchase securities at
the public offering price under delayed delivery contracts. These contracts would provide for payment and delivery on a specified
date in the future. The contracts would be subject only to those conditions described in the prospectus supplement. The applicable
prospectus supplement will describe the commission payable for solicitation of those contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Continuous Offering Program</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Without limiting the generality of the foregoing,
we may enter into a continuous offering program equity distribution agreement with a broker-dealer, under which we may offer and
sell shares of our common stock from time to time through a broker-dealer as our sales agent. If we enter into such a program,
sales of the shares of common stock, if any, will be made by means of ordinary brokers&rsquo; transactions on the NASDAQ Capital
Market at market prices, block transactions and such other transactions as agreed upon by us and the broker-dealer. Under the terms
of such a program, we also may sell shares of common stock to the broker-dealer, as principal for its own account at a price agreed
upon at the time of sale. If we sell shares of common stock to such broker-dealer as principal, we will enter into a separate terms
agreement with such broker-dealer, and we will describe this agreement in a separate prospectus supplement or pricing supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Market Making, Stabilization and Other Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Unless the applicable prospectus supplement
states otherwise, other than our common stock all securities we offer under this prospectus will be a new issue and will have no
established trading market. We may elect to list offered securities on an exchange or in the over-the-counter market. Any underwriters
that we use in the sale of offered securities may make a market in such securities, but may discontinue such market making at any
time without notice. Therefore, we cannot assure you that the securities will have a liquid trading market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any underwriter may also engage in stabilizing
transactions, syndicate covering transactions and penalty bids in accordance with Rule&nbsp;104 under the Securities Exchange Act.
Stabilizing transactions involve bids to purchase the underlying security in the open market for the purpose of pegging, fixing
or maintaining the price of the securities. Syndicate covering transactions involve purchases of the securities in the open market
after the distribution has been completed in order to cover syndicate short positions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Penalty bids permit the underwriters to
reclaim a selling concession from a syndicate member when the securities originally sold by the syndicate member are purchased
in a syndicate covering transaction to cover syndicate short positions. Stabilizing transactions, syndicate covering transactions
and penalty bids may cause the price of the securities to be higher than it would be in the absence of the transactions. The underwriters
may, if they commence these transactions, discontinue them at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>General Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Agents, underwriters, and dealers may be
entitled, under agreements entered into with us, to indemnification by us against certain liabilities, including liabilities under
the Securities Act. Our agents, underwriters, and dealers, or their affiliates, may be customers of, engage in transactions with
or perform services for us, in the ordinary course of business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_010"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">The validity of the
issuance of the securities offered by this prospectus will be passed upon for us by Sichenzia Ross Ference LLP, New York, New York.
Sichenzia Ross Ference LLP or certain members or employees of Sichenzia Ross Ference LLP have been issued common stock of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_011"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The consolidated financial statements of
INmune Bio Inc. as of and for the years ended December&nbsp;31, 2019 and 2018 appearing in INmune Bio Inc.&rsquo;s Annual Report
on Form 10-K for the year ended December&nbsp;31, 2019, have been audited by Marcum LLP, as set forth in its report thereon, included
therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance
upon such report given on the authority of such firm as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="b_012"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We file annual, quarterly and special reports,
along with other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&rsquo;s website
at http://www.sec.gov. You may also read and copy any document we file at the SEC&rsquo;s Public Reference Room at 100 F Street,
NE, Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus is part of a registration
statement on Form S-3 that we filed with the SEC to register the securities offered hereby under the Securities Act of 1933, as
amended. This prospectus does not contain all of the information included in the registration statement, including certain exhibits
and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address
listed above or from the SEC&rsquo;s internet site.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in"><B><A NAME="b_013"></A>INCORPORATION OF
CERTAIN DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This prospectus is part of a registration
statement filed with the SEC. The SEC allows us to &ldquo;incorporate by reference&rdquo; into this prospectus the information
that we file with them, which means that we can disclose important information to you by referring you to those documents. The
information incorporated by reference is considered to be part of this prospectus, and information that we file later with the
SEC will automatically update and supersede this information. The following documents are incorporated by reference and made a
part of this prospectus:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390020005916/f10k2019_inmunebioinc.htm">Form 10-K</A> for the year ended December 31, 2019 filed with the SEC on March 11, 2020;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our Current Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000121390020006109/ea119517-8k_inmunebio.htm">Form 8-K</A> filed with the SEC on March 12, 2020;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the description of our common stock contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1711754/000164033419000136/inmune_8a12b.htm">Form 8-A</A> filed with the SEC on February 1, 2019 (File No. 001-38793), including any amendment or report filed for the purpose of updating such description; and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 48px">&nbsp;</TD>
    <TD STYLE="width: 24px"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all reports and other documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act after the date of this prospectus and prior to the termination of this offering.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">We also incorporate by reference any future
filings (other than information furnished under Item&nbsp;2.02 or Item&nbsp;7.01 of Form&nbsp;8-K and exhibits furnished on such
form that are related to such items unless such Form&nbsp;8-K expressly provides to the contrary) made with the SEC pursuant to
Sections&nbsp;13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act, including those made after the date of the initial filing of
the registration statement of which this prospectus is a part and prior to effectiveness of such registration statement, until
we file a post-effective amendment that indicates the termination of the offering of the common stock made by this prospectus and
will become a part of this prospectus from the date that such documents are filed with the SEC. Information in such future filings
updates and supplements the information provided in this prospectus. Any statements in any such future filings will automatically
be deemed to modify and supersede any information in any document we previously filed with the SEC that is incorporated or deemed
to be incorporated herein by reference to the extent that statements in the later filed document modify or replace such earlier
statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Notwithstanding the foregoing, information
furnished under Items 2.02 and 7.01 of any Current Report on Form 8-K, including the related exhibits, is not incorporated by reference
in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information about us contained in this
prospectus should be read together with the information in the documents incorporated by reference. You may request a copy of any
or all of these filings, at no cost, by writing or telephoning us at: David Moss, INmune Bio Inc., 1200 Prospect Street, Suite
525, La Jolla, CA 92037, telephone number (858) 964-3720.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<IMG SRC="image_001.jpg" ALT="" STYLE="height: 175px; width: 262px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>$45,000,000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INMUNE BIO, INC. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="image_002.jpg" ALT="" STYLE="height: 85px; width: 330px">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus supplement
is March 10, 2021 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "O 08# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HK+U'7]/TPE9YP9,?ZM.6_^M7+WOCZ
M4!OL]O%&@_BE/ZUK"C.>R.6MC:-)VE+7RU.\HKRB;XESQL0;^V'L$!_E3[;X
MJ@./-FMY!WW*5K;ZE6ML8+,Z+Z/[CU2D+!<9(&3@5R^D>.](U-<-.D,GINRO
MYUI:[>"#2EN8W!Q(A5@>#S6#I34N62L=/UFFX.<7>QKT4BL&4,.A&:6LSH"B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M*  G R:XO7/%4EQ*;#259G8[3*HY/LO^-6?%^N-:Q#3[5B)Y1\Y7J%/;ZFN(
MU^XGT"VMM+TO,FOWW#>7RT"'L/1CZ^F:[,/0O9OKM_FSRL7B)3DZ5-V2W?Z+
MS,G6M773KQK*-3=ZD6VLBG*HWH3U8^P_.K>F_##Q!KCBXUFZ%E$WS>6?F?\
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MC[-IIW3V9Z="KSIIJS70DHHHKG-PHHHH **** "BBB@ HHHH **** "BBB@
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MMU_URC_]!KHE2A5KQC-77*81JRIT7*+^T=G<_&&T318IX+3=J$A(,!)VQ@'
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MKF/#7Q0/B'7[;2QI9A\[=F3S,[< GI^%4+PD_ >')S^Z3_T.N,^&?_(_:?\
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0W!0Z;B4$I.?4****@L__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !5 4H# 2(  A$! Q$!_\0
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M6$X)"*2>E>.?V/J?_0/NO^_1KU\&TJ6I\]F,9.N[+L4J[/X>_P"LUW_L&O\
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MI.3_ *3*I^(GBC)_XF9Z_P#/-?\ "C_A8GBC_H)'_OVO^%<N>I^M)6OL:?\
M*C#ZQ5_F?WG4_P#"Q/%'_02/_?M?\*/^%B>*/^@D?^_:_P"%<M1UX%'LJ?\
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ME9$;>$M&=MSVS,?4R,?ZT+X2T9#N6U*GU$C#^M%%+E0[C_\ A&=,_P"><O\
MW^;_ !J-O"6C.?FMF;ZR,?ZT44^5"N2P>&-'MSE+*,_[V6_G6LD:1H%1%51T
M &***25ACJ***8"$9!!K(/AK3&8L8Y<DY/[YO\:**+7 C?PGH\A!>V9C_M2,
M?ZT@\(Z*K BT((Z$2-_C112Y4%V2?\(SIG_/.7_O\W^-:5I:Q6=NL$((1>@+
M$_SHHIV0$],EB6:)HW!*L,'!Q110!D_\(SIG_/.7_O\ -_C49\(Z*Q)-H23U
M)=O\:**.5"NQ4\*:/&3LMV7_ '9&']:L6_A_3[:=)XDD#H<C,K$?SHHI60[F
MI1113 SM0T/3M2&;FV1F_O#@_F*Y2Z@DT5V6QO+F-!R$+Y _#%%%1):7 J0:
M[JEQ)Y;WTH!_NX!_E6]9:%:ZB!)?2W%R<9Q+*2!^ HHJ8ZO4;.BMK*VLT"6\
0"1J.RC%3T45J(**** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
